5 of Last Week's Biggest Winners

What's better than momentum? Mo' momentum. Let's take a closer look at five of this past week's biggest scorchers.


Nov. 29

Weekly Gain

Ariad Pharmaceuticals  (NASDAQ: ARIA  )



Sarepta Therapeutics  (NASDAQ: SRPT  )



J.C. Penney  (NYSE: JCP  )



Voxeljet  (NYSE: VJET  )



SolarCity  (NASDAQ: SCTY  )



Source: Barron's.

Let's start with Ariad. The biotech moved sharply higher on encouraging news in Europe. Its leukemia drug Iclusig will continue to be offered in Europe, even though the regulatory agency is suggesting some safety protocols. 

Sarepta was the Nasdaq's biggest loser three weeks ago, surrendering 60% of its value when the FDA delayed the biotech's application for its Duchenne muscular dystrophy drug. Some investors are starting to sense a buying opportunity in the rubble, and on Tuesday it was upgraded by WBB Securities. 

J.C. Penney broke into double digits for the first time in more than two months after some timely insider buying. The struggling department-store chain's CEO bought roughly $1 million of J.C. Penney's stock. It's his first purchase in years, giving the open market purchase more weight in shaping bullish opinion than usual. 

Voxeljet moved higher even as Jim Cramer had some unkind words to say about the recent 3-D printing IPO.

"When Voxeljet becomes an earnings story, I am willing to listen," he said on CNBC's Squawk on the Street show. "Right now, they are the poster boy for overvalued."

SolarCity lost 16% of its value a week earlier, but it made most of that amount back during this holiday-shortened trading week. An important catalyst was announcing the opening of 10 regional operation centers across California. The move nearly doubles the solar-energy installer's presence in California.

Keep the good vibes coming
The market stormed out to huge gains across 2013, leaving investors on the sidelines burned. However, opportunistic investors can still find huge winners. The Motley Fool's chief investment officer has just hand-picked one such opportunity in our new report: "The Motley Fool's Top Stock for 2014." To find out which stock it is and read our in-depth report, simply click here. It's free!

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2747768, ~/Articles/ArticleHandler.aspx, 7/13/2014 10:30:00 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...